Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...
Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...
UTOPIA Phase 3 Trial of UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC - Abhishek Srivastava
Abhishek Srivastava presents UTOPIA trial data, covering UGN-103, a reformulation of intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle-invasive ...
Aurea Molina Diaz discusses the PrInCIS-NIADY, a nationwide Spanish real-world study of adjuvant nivolumab in patients with high-risk PD-L1-positive muscle-invasive urothelial carcinoma following ...
Juan Ruiz-Bañobre presents an ultrasensitive ctDNA analysis in advanced clear cell RCC, using a tumor-informed whole genome sequencing assay on serial plasma samples from 37 treatment-naive patients ...
Ronald Chen presents quality of life results from the AMBASSADOR trial, a randomized study of adjuvant pembrolizumab versus observation in high-risk urothelial carcinoma after radical surgery. Quality ...
The fourth episode in this podcast series features a discussion between the two principal investigators from the phase III EMBARK trial (NCT02319837). EMBARK showed that in patients with prostate ...
Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
Appropriately selected combined operations have the potential to further increase the efficiency and cost-effectiveness of robotic urologic surgeries. This is particularly relevant for older patients ...
Loss of the PTEN tumor suppressor gene is a common molecular feature in advanced prostate cancer and is associated with activation of the PI3K/AKT signaling pathway, which controls cell growth and ...
The majority of bladder cancers are diagnosed as non-muscle invasive (NMIBC), with 90% over the age of 55. Although the incidence of several malignancies is increasing among younger adults in whom ...
To define the time course of fracture risk with radium-223 in combination with androgen receptor pathway inhibitor (ARPi) therapy and assess the clinical impact of concomitant bone-protective agent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results